* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patient...
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinic...
* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary ...
* Two-year research collaboration to develop new reactive group chemistries targeting non-cystein...
* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seek...
* Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via ...
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced to...
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealan...
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clin...
SEONGNAM, South Korea, Nov. 9, 2020 /PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (28...
SEONGNAM, South Korea and BASEL, Switzerland, July 14, 2020 /PRNewswire/ -- Bridge Biotherapeutics ...
* Following the US FDA's IND clearance, South Korea's MFDS cleared the IND application of BBT-176...
* The Interim data showed that 3 out of 9 evaluable patients on BBT-401 responded with more than ...
* Signed a collaboration and license agreement for developing back-eye disease treatments with Ko...
SEONGNAM, South Korea, Jan. 19, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage ...
* China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 * The Phase...
SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage ...